Stellar Biotechnologies, Inc. (NASDAQ:SBOT) posted its earnings results on Wednesday. The biotechnology company reported ($0.12) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.12), Bloomberg Earnings reports. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.34 million. Stellar Biotechnologies had a negative return on equity of 50.56% and a negative net margin of 774.21%.

Stellar Biotechnologies (SBOT) traded down 8.06% during mid-day trading on Thursday, hitting $1.14. The company had a trading volume of 41,357 shares. The company’s market cap is $11.56 million. Stellar Biotechnologies has a one year low of $1.05 and a one year high of $3.00. The company’s 50 day moving average price is $1.31 and its 200-day moving average price is $1.45.

TRADEMARK VIOLATION NOTICE: “Stellar Biotechnologies, Inc. (NASDAQ:SBOT) Announces Quarterly Earnings Results” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/stellar-biotechnologies-inc-nasdaqsbot-announces-quarterly-earnings-results/1471092.html.

About Stellar Biotechnologies

Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.

Receive News & Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.